Liquidia Stock (NASDAQ:LQDA)
Previous Close
$9.72
52W Range
$5.71 - $16.99
50D Avg
$11.10
200D Avg
$12.34
Market Cap
$815.48M
Avg Vol (3M)
$1.24M
Beta
0.22
Div Yield
-
LQDA Company Profile
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
LQDA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| XFOR | X4 Pharmaceuticals, Inc. |
| GOSS | Gossamer Bio, Inc. |
| KALV | KalVista Pharmaceuticals, Inc. |
| LRMR | Larimar Therapeutics, Inc. |
| IMCR | Immunocore Holdings plc |
| BMRN | BioMarin Pharmaceutical Inc. |
| LEGN | Legend Biotech Corporation |
| REPL | Replimune Group, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| KRON | Kronos Bio, Inc. |
| INZY | Inozyme Pharma, Inc. |
| AGEN | Agenus Inc. |
| NRXP | NRx Pharmaceuticals, Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |
| GERN | Geron Corporation |
| PCVX | Vaxcyte, Inc. |
| UTHR | United Therapeutics Corporation |
| TECH | Bio-Techne Corporation |
| LYRA | Lyra Therapeutics, Inc. |
| NVCT | Nuvectis Pharma, Inc. |
| AMLX | Amylyx Pharmaceuticals, Inc. |
| MIRM | Mirum Pharmaceuticals, Inc. |